文献速递神经MR

酰胺质子转移加权化学交换饱和转移MRI鉴别胶质瘤复发与假性进展

Differentiating Glioma Recurrence and Pseudoprogression by APTw CEST MRI.
PubMed 文献 · Invest Radiol · 2024-12-09

这项单中心前瞻性研究纳入30例复发胶质瘤和12例假性进展患者,在3 T MRI上加做酰胺质子转移加权(APTw)成像。结果显示,复发患者APTw值高于假性进展患者(1.99% vs 1.26%,P=0.008),且复发时切除腔APTw较复发前升高(0.6% vs 2.68%,P=0.03)。作者认为APTw成像可鉴别复发与假性进展。

要点

  • 复发胶质瘤实性强化区APTw值高于非强化FLAIR病灶(1.99% vs 1.36%,P=0.001)。
  • 复发患者APTw值高于假性进展患者(1.99% vs 1.26%,P=0.008)。
  • 复发时切除腔APTw较复发前升高(0.6% vs 2.68%,P=0.03),假性进展者无此变化。

核心结论

  • APTw成像可鉴别复发胶质瘤与假性进展,并能发现常规序列无法检测的复发相关影像模式,包括与疾病进展相关的切除腔改变。

研究设计与样本

  • 单中心前瞻性研究,2021年8月至2024年3月筛查371例胶质瘤患者,纳入30例复发胶质瘤和12例假性进展患者;采用3 T MRI,含FLAIR、T1加权钆增强序列和APTw成像;按WHO 2021分类分级,按RANO标准评估疗效。

关键影像表现/征象

  • 实性钆强化肿瘤区APTw值最高(1.99%),高于非强化FLAIR病灶(1.36%),P=0.001。
  • 正常表现白质APTw值为0.005%,与FLAIR病灶相比P<0.001。
  • 化学交换饱和转移可显示FLAIR病灶内常规序列无法检测的异质性。
  • 强化病灶内可见局灶性APTw信号峰值,为复发胶质瘤的推定代谢热点。
  • 复发时切除腔出现APTw升高(复发前0.6% vs 复发时2.68%,P=0.03),复发前及假性进展患者中均未检测到。

诊断标准与关键数值

  • 复发患者APTw值1.99% vs 假性进展患者1.26%,P=0.008。
  • 实性强化肿瘤区APTw值1.99% vs 非强化FLAIR病灶1.36%,P=0.001。
  • 正常表现白质APTw值0.005%,与FLAIR病灶相比P<0.001。
  • 切除腔APTw值复发前0.6% vs 复发时2.68%,P=0.03。

临床应用与阅片要点

  • APTw成像可在常规FLAIR和T1加权钆增强序列基础上,用于胶质瘤复发与假性进展的鉴别。
  • 阅片时关注强化病灶内局灶性APTw信号峰值,可能代表复发胶质瘤的代谢热点。
  • 切除腔出现APTw升高可能提示疾病进展,需结合复发前后对比观察。
  • APTw可显示FLAIR病灶内常规序列无法检测的异质性,有助于评估肿瘤分子异质性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: Recurrent glioma is highly treatment resistant due to its metabolic, cellular, and molecular heterogeneity and invasiveness. Tumor monitoring by conventional MRI has shortcomings to assess these key glioma characteristics. Recent studies introduced chemical exchange saturation transfer for metabolic imaging in oncology and assessed its diagnostic value for newly diagnosed glioma. This prospective study investigates amide proton transfer-weighted (APTw) MRI at 3 T as an imaging biomarker to elucidate the molecular heterogeneity and invasion patterns of recurrent glioma in comparison to pseudoprogression (PsPD).

MATERIALS AND METHODS: We performed a monocenter, prospective trial and screened 371 glioma patients who received tumor monitoring between August 2021 and March 2024 at our institution. The study included IDH wildtype astrocytoma and IDH mutant astrocytoma and oligodendroglioma, graded according to the WHO 2021 classification. Patients had received clinical standard of care treatment including surgical resection and radiochemotherapy prior to study inclusion. Patients were monitored by 3 monthly MRI follow-up imaging, and response assessment was performed according to the RANO criteria. Within this cohort, we identified 30 patients who presented with recurrent glioma and 12 patients with PsPD. In addition to standard anatomical sequences (FLAIR and T1-w Gd-enhanced sequences), MRI included APTw imaging. After sequence co-registration, semiautomated segmentation was performed of the FLAIR lesion, CE lesion, resection cavity, and the contralateral normal-appearing white matter, and APTw signals were quantified in these regions of interest.

RESULTS: APTw values were highest in solid, Gd-enhancing tumor parts as compared with the nonenhancing FLAIR lesion (APTw: 1.99% vs 1.36%, P = 0.001), whereas there were no detectable APTw alterations in the normal-appearing white matter (APTw: 0.005%, P < 0.001 compared with FLAIR). Patients with progressive disease had higher APTw levels compared with patients with PsPD (APTw: 1.99% vs 1.26%, P = 0.008). Chemical exchange saturation transfer identified heterogeneity within the FLAIR lesion that was not detectable by conventional sequences. There were also focal APTw signal peaks within contrast enhancing lesions as putative metabolic hotspots within recurrent glioma. The resection cavity developed an APTw increase at recurrence that was not detectable prior to recurrence nor in patients with PsPD (APTw before recurrence: 0.6% vs 2.68% at recurrence, P = 0.03).

CONCLUSIONS: Our study shows that APTw imaging can differentiate PD and PsPD. We identify previously undetectable imaging patterns during glioma recurrence, which include alterations within resection cavity associated with disease progression. Our work highlights the clinical potential of APTw imaging for glioma monitoring and further establishes it as an imaging biomarker in neuro-oncology.

来源:Invest Radiol,查看原文。版权归原作者所有。

引用

  1. Karimian-Jazi K, Enbergs N, Golubtsov E, et al. Differentiating Glioma Recurrence and Pseudoprogression by APTw CEST MRI. Invest Radiol. 2024. PMID: 39644107. doi:10.1097/RLI.0000000000001145

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。